[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prostatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prostatitis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100579319","phase-3-fosfomycin-for-male-urinary-tract-infection-100579319",false,"NCT06822751","FOsfomycin for Male Urinary Tract Infection","Exploratory Pragmatic Trial of Fosfomycin-trometamol Treatment of Male Urinary Tract Infections in Primary Care","FOMUTI","Inclusion Criteria:\n\n* Men aged 18 years or older.\n* Consulting in a primary care setting.\n* Suspected of having a male urinary tract infection (MUTI) by the investigating physician and presenting at least one recent acute symptom (\\\u003C 3 months) from the following:\n\n  * Lower urinary tract symptoms: dysuria, urgency, frequency, hematuria.\n  * Pelvic pain unrelated to urination: suprapubic, perineal, or urethral pain.\n* Patient has read and understood the information letter and signed the informed consent form.\n* Affiliation with a social security system or beneficiary of such a system.\n* No history of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participation in the protocol or to prevent him\u002Fher from giving informed consent\n\nExclusion Criteria:\n\n* Presence of one or more criteria for severity of infection\n\n  * Severe sepsis or septic shock defined by a qSOFA score ≥ 2\n  * or\u002Fand systolic BP less than 100 mmHg: non-inclusion criterion\n  * or\u002Fand temperature \\\u003C 36°C or \\> 38°C\n  * or\u002Fand diagnosis of pyelonephritis (pain on lumbar percussion)\n  * or\u002Fand presence of abdominal guarding\u002Fcontraction\n  * or\u002Fand presence of a bladder globe above the pubic bone: (suspected acute retention of urine)\n  * or\u002Fand known immunosuppression: any immunosuppressive treatment (including corticosteroid therapy \\> 10 mg\u002Fd for more than 5 days), neutropenia (PNN \\\u003C 500\u002FmL) severe malnutrition (albumin \\\u003C 30 and\u002For BMI \\\u003C 16),\n* No diagnosis of male urinary tract infection in the last 3 months,\n* No ongoing chronic prostatitis,\n* Known urinary tract abnormality: urinary tract lithiasis, vesico-ureteral reflux, prostate or urinary tract cancer, prostate adenoma treated medically or surgically, urinary tract malformation (including single kidney and urethral stricture).\n* Acute retention of urine and indication for surgical or interventional drainage\n* Hyperalgesic form\n* Urinary tract infection associated with care, on urinary catheter or suprapubic catheter\n* Urinary tract surgery, cystoscopy, prostate biopsy or urinary catheterisation less than 3 months old\n* Urinary tract surgery, cystoscopy, prostate biopsy or urinary catheterisation less than 3 months old\n* Severe disease or high probability of death within 3 months,\n* Hypersensitivity to fosfomycin trometamol or to any of the excipients (notable excipients: sucrose, dextrose (source of glucose), maltodextrin (source of glucose), orange yellow colouring S (E110)),\n* End-stage renal disease (creatinine clearance \\\u003C10 mL\u002Fmin),\n* Patients with glucose and galactose malabsorption syndrome or sucrase\u002Fisomaltase deficiency (rare hereditary disease)\n* Antibiotic taken within 72 hours of diagnosis of male urinary tract infection,\n* Major cognitive impairment,\n* Person deprived of liberty by an administrative or judicial decision or person placed under court protection \u002F sub- guardianship or curatorship\n* Any history of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participation in the protocol or to prevent the subject from giving informed consent.\n* Known non-adherence to treatment,\n* Simultaneous participation in another interventional clinical study,\n* Cannot be taken orally (vomiting)","MALE","18 Years",{"count":20,"type":21},138,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Male urinary tract infections (MUTI) are often less recognised compared to those in women. French clinical guidelines practices recommend the use of antibiotics called fluoroquinolones, which are highly effective in treating MUTIs. However, these antibiotics can lead to rare but serious side effects, such as tendonitis or heart rhythm disturbances. Additionally, fluoroquinolones can contribute to the development of bacterial resistance, making their use inadvisable within six months of treatment.\n\nIn response to these concerns, we aim to explore a well-established alternative, fosfomycin trometamol (known by the brand name MONURIL®). This antibiotic has a strong track record in treating UTIs in women, with well-documented benefits and minimal associated risks.\n\nThe primary goal of this study is to assess the effectiveness of fosfomycin trometamol in treating urinary tract infections in men, as well as to evaluate any potential treatment failures.",[27,28,29],"Urinary Tract Infection","Prostatitis","Cystitis",[31,29,27,32,33],"Men","Anti-infective agents, urinary","Fosfomycin","NOT_YET_RECRUITING","2026-06-11",{"date":37,"type":38},"2026-06-12","ACTUAL",{"date":40,"type":21},"2026-07",{"date":42,"type":21},"2029-10",{"name":44,"class":45},"University Hospital, Rouen","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":46},"100617870","tecar-therapy-on-pain-and-quality-of-life-in-men-with-chronic-prostatitischronic-pelvic-pain-syndrome-100617870","NCT07324239","TECAR Therapy on Pain and Quality of Life in Men With Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome","Effect of TECAR Therapy on Pain and Quality of Life in Men With Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Presence of chronic prostatitis\u002Fchronic pelvic pain symptoms for more than 6 months.\n* Ages will be ranged from 30 to 50 years old.\n\nExclusion Criteria:\n\n1. Urinary and seminal infections.\n2. Recent parenteral steroid administration.\n3. Prior prostate or pelvic surgery.\n4. Lower urinary tract disorders such as bladder stones.\n5. Implanted electronic devices as pacemakers.\n6. Sensory loss over the perineum.","30 Years","50 Years",{"count":57,"type":21},60,[59],"NA","Evaluate the effect of TECAR therapy on pain, voiding, erectile function, sleep quality and quality of life in men with chronic prostatitis\u002Fchronic pelvic pain syndrome.",[28],"2025-12-23",{"date":64,"type":38},"2026-01-07",{"date":66,"type":21},"2026-01-02",{"date":68,"type":21},"2026-04-07",{"name":70,"class":45},"Middle East University",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":46},"100590957","effect-of-graminex-on-infertility-related-to-male-accessory-glands-inflammation-100590957","NCT06974175","Effect of Graminex on Infertility Related to Male Accessory Glands Inflammation","Effect of Graminex on Infertility Related to Male Accessory Glands Inflammation. Pilot Study","DEPR_1","Inclusion Criteria:\n\n* Male patients with a diagnosis of MAGI based on clinical and\u002For ultrasonographic criteria.\n\nExclusion Criteria:\n\n* History of cryptorchidism, orchitis, testicular torsion or trauma,\n* Hypogonadism,\n* Occupational chemical exposure,\n* Y chromosome microdeletions, karyotype abnormalities and Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) mutations,\n* ultrasound testicular volume \\\u003C12 mL,\n* FSH \\>8 mUI\u002FL,\n* fever or drug use within 3 months prior to the enrollment in this study\n* azoospermia.","20 Years","55 Years",{"count":82,"type":21},50,[59],"Male Accessory Glands Inflammations (MAGI) include inflammatory diseases involving seminal vescicles and the prostate. Patients suffering from them present an impaired fertility because of seminal duct obstruction and alterations of the rheologic and functional parameters of semen, induced by direct microbiological action as well as inflammatory and oxidative damage. Inflammation in seminal plasma can be detected and measured by dosing of inflammatory molecules such as SuPAR and ST2. Treatment of MAGIs include specific antibiotic therapy in addition to use of anti-inflammatory nutraceutics. Deprox HP is a nutraceutic containing GraminexTM, a compound made of pollen extracts of rye, mais and timothy. To investigate its efficacy, we evalued seminal parameters, inflammatory and oxidative molecules in seminal plasma and clinical and ultrasonographic features of male accessory glands before and after 3 months of treatment in 20 patients taking Deprox HP and 20 patients undergoing treatment with palmitoilethanolammide, bromelin and horse chestnut extract.",[86,28],"Male Infertility","2025-08-13",{"date":89,"type":38},"2025-08-14",{"date":91,"type":21},"2025-09-01",{"date":93,"type":21},"2026-05-01",{"name":95,"class":45},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS"]